Lifebit Platform selected to power secure data analytics platform for transformative lung cancer study

A single-arm phase 2 study assessed local consolidative therapy regimens in patients with oligometastatic stage IV non–small cell lung carcinoma.

Following the Trump administration's DEI ban, the FDA's move to scrub webpages has ensnared many pages focused on ensuring diversity in drug trials.

The Lung Cancer Genetics Study, a collaboration between lung cancer advocacy organizations, aims to explore the genetics of lung cancer

Limertinib was approved in China for locally advanced or metastatic non–small cell lung cancer harboring an EGFR T790M mutation.

The report is the latest indictment of America’s broken healthcare system.

After losing half a lung, Katie Gilmore is now combining two important aspects of her life—running and raising awareness of lung cancer.

Dianne Covey's lung cancer was detected at Stage 1 and her prognosis is positive, says the hospital.

The EPA has banned two chemicals — known as TCE and perc — commonly found in dry cleaning solutions and stain removers.

EGFR tyrosine kinase inhibitor (EGFR-TKI)-sensitizing and -resistance mutations may be detected in plasma through circulating tumor DNA (ctDNA). Circulating tumor DNA level changes reflect alterations in tumor burden and could be a dynamic indicator of treatment effect. This analysis aimed to determine whether longitudinal EGFR-mutation ctDNA testing could detect progressive disease (PD) before radiologic detection.